Cue Biopharma (NASDAQ:CUE) Trading Down 3.8% - Should You Sell?

Key Points

• Cue Biopharma shares fell 3.8% to $26.10 in midday trading, with volume about 85% above the average session level. The stock remains well below its 50-day moving average of $29.31 and 200-day moving average of $154.54.
• Analyst sentiment remains negative overall: although Wall Street Zen upgraded the stock to “buy,” Weiss Ratings moved it to “sell (d-),” and MarketBeat reports a consensus “Sell” rating.
• The company beat quarterly expectations, reporting a loss of $1.08 per share versus the projected $3.30 loss and revenue of $5.69 million versus $2.50 million expected. However, Cue Biopharma continues to post negative profitability metrics, including a 98.3% negative return on equity and a 59.65% negative net margin.

Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) fell 3.8% during mid-day trading on Monday . The company traded as low as $24.80 and last traded at $26.10. Approximately 315,940 shares changed hands during mid-day trading, an increase of 85% from the average session volume of 170,606 shares. The stock had previously closed at $27.12.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Cue Biopharma from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, May 18th. Wall Street Zen raised shares of Cue Biopharma from a "hold" rating to a "buy" rating in a research report on Saturday, June 6th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of "Sell".

Cue Biopharma Price Performance

The firm's fifty day moving average price is $29.31 and its two-hundred day moving average price is $154.54. The stock has a market cap of $109.62 million, a price-to-earnings ratio of -4.67 and a beta of 2.47.

Cue Biopharma (NASDAQ:CUE - Get Free Report) last issued its earnings results on Thursday, May 14th. The company reported ($1.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.30) by $2.22. The company had revenue of $5.69 million for the quarter, compared to analysts' expectations of $2.50 million. Cue Biopharma had a negative return on equity of 98.30% and a negative net margin of 59.65%.

Hedge Funds Weigh In On Cue Biopharma

Hedge funds have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. lifted its position in shares of Cue Biopharma by 730.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company's stock valued at $57,000 after purchasing an additional 73,000 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Cue Biopharma during the 3rd quarter worth approximately $62,000. Stifel Financial Corp boosted its stake in shares of Cue Biopharma by 25.4% in the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company's stock worth $75,000 after buying an additional 50,000 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc boosted its stake in shares of Cue Biopharma by 1,231.2% in the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company's stock worth $135,000 after buying an additional 407,568 shares during the last quarter. Finally, Boothbay Fund Management LLC boosted its position in Cue Biopharma by 15.3% in the fourth quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company's stock worth $215,000 after purchasing an additional 93,333 shares during the last quarter. 35.04% of the stock is owned by hedge funds and other institutional investors.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company's proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source